Long-acting somatostatin analogs and well differentiated neuroendocrine tumors: a 20-year-old story
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
Long-acting somatostatin analogs and well differentiated neuroendocrine tumors: a 20-year-old story ; day:15 ; month:8 ; year:2023 ; pages:1-12
Journal of endocrinological investigation ; (15.8.2023), 1-12
- Creator
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40618-023-02170-9
- URN
-
urn:nbn:de:101:1-2023110310273163836989
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:44 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Faggiano, Antongiulio
- SpringerLink (Online service)
Other Objects (12)
Patients’ satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors
Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Safety review: Dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients
Somatostatin analogs in cancer management : 16 tables
Radiolabeled Somatostatin receptor analogs in neuroendocrine tumor : novel applications and clinical indications for in-vivo tumor characterization
Predictive value of 68[Ga]Ga-DOTA-TATE PET/CT volumetric parameters in assessing treatment response to long-acting somatostatin analogues in patients with well-differentiated neuroendocrine tumours
Treatment with somatostatin analogs induces differentially expressed let-7c-5p and mir-3137 in small intestine neuroendocrine tumors
Pelvic MRI, FDG-PET/CT, and Somatostatin Receptor Scintigraphy Findings of Treatment-Related Neuroendocrine-Differentiated Prostate Cancer
The Coordination Abilities of New Cyclic Analogs of Somatostatin
A case of malignant insulinoma responsive to somatostatin analogs treatment
Complete remission of recurrent multiple insulin-producing neuroendocrine tumors of the pancreas with somatostatin analogs: a case report and literature review
Patients’ satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors
Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Safety review: Dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients
Somatostatin analogs in cancer management : 16 tables
Radiolabeled Somatostatin receptor analogs in neuroendocrine tumor : novel applications and clinical indications for in-vivo tumor characterization
Predictive value of 68[Ga]Ga-DOTA-TATE PET/CT volumetric parameters in assessing treatment response to long-acting somatostatin analogues in patients with well-differentiated neuroendocrine tumours
Treatment with somatostatin analogs induces differentially expressed let-7c-5p and mir-3137 in small intestine neuroendocrine tumors
Pelvic MRI, FDG-PET/CT, and Somatostatin Receptor Scintigraphy Findings of Treatment-Related Neuroendocrine-Differentiated Prostate Cancer
The Coordination Abilities of New Cyclic Analogs of Somatostatin
A case of malignant insulinoma responsive to somatostatin analogs treatment
Complete remission of recurrent multiple insulin-producing neuroendocrine tumors of the pancreas with somatostatin analogs: a case report and literature review
Patients’ satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors
Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Safety review: Dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients
Somatostatin analogs in cancer management : 16 tables
Radiolabeled Somatostatin receptor analogs in neuroendocrine tumor : novel applications and clinical indications for in-vivo tumor characterization
Predictive value of 68[Ga]Ga-DOTA-TATE PET/CT volumetric parameters in assessing treatment response to long-acting somatostatin analogues in patients with well-differentiated neuroendocrine tumours
Treatment with somatostatin analogs induces differentially expressed let-7c-5p and mir-3137 in small intestine neuroendocrine tumors
Pelvic MRI, FDG-PET/CT, and Somatostatin Receptor Scintigraphy Findings of Treatment-Related Neuroendocrine-Differentiated Prostate Cancer
The Coordination Abilities of New Cyclic Analogs of Somatostatin
A case of malignant insulinoma responsive to somatostatin analogs treatment